Roche’s Vabysmo Chases Regeneron’s Eylea With New Pivotal Macular Edema Wins

The Swiss major’s new bispecific antibody could challenge Eylea’s standard of care status in another ophthalmic indication, macular edema due to retinal vein occlusion, but the older rival is set to hit back in bigger markets with a high-dose reformulation.